Assurerx Health is a technology company.
Assurerx Health has raised $78.3M across 6 funding rounds.
Assurerx Health has raised $78.3M in total across 6 funding rounds.
# Assurex Health: A Personalized Medicine Pioneer
Assurex Health is a personalized medicine company specializing in pharmacogenomics—the study of how genetic factors influence individual responses to medications[2][4]. The company develops and commercializes genetic testing technology to help healthcare providers determine the most appropriate medications and dosages for patients with neuropsychiatric and chronic pain conditions[1][4].
The company's flagship product, GeneSight®, is a lab-developed pharmacogenetic test that combines genetic testing with algorithmic interpretation to guide physicians in prescribing psychiatric medications[1]. Rather than a one-size-fits-all approach to mental health treatment, Assurex Health enables clinicians to make data-driven medication decisions based on each patient's unique genetic profile, ultimately improving treatment outcomes and reducing healthcare costs[4].
Founded in 2006 and based in Mason, Ohio, Assurex Health emerged from a strategic partnership with two world-renowned medical institutions[2][4]. The company licensed patented technology from Cincinnati Children's Hospital Medical Center and Mayo Clinic, both of which continued as research collaborators[2][4]. This institutional backing provided credibility and scientific rigor from inception.
The company received early support from CincyTech (a seed fund), local angel investors, and regional economic development programs including Ohio's JobsOhio initiative[4]. By 2012, Assurex Health had gained sufficient traction to win the Luis Villalobos Award for innovation from the Angel Capital Association, with backing from regional angel groups including Queen City Angels, Ohio Tech Angels, and the North Coast Angel Fund[2].
Assurex Health operates at the intersection of precision medicine and digital health, riding the broader shift toward individualized treatment protocols in healthcare. The company addresses a fundamental challenge in psychiatry: medication selection remains largely trial-and-error, with patients often cycling through multiple drugs before finding effective treatment. By introducing genetic science into this decision-making process, Assurex Health helps reduce treatment delays, improve patient outcomes, and lower overall healthcare expenditures—aligning with healthcare systems' cost-containment priorities.
The company's success reflects growing recognition that pharmacogenomics is clinically and economically valuable, particularly in mental health treatment where medication efficacy varies dramatically between individuals. This positions Assurex Health within the broader personalized medicine ecosystem alongside molecular diagnostics leaders.
In August 2016, Assurex Health was acquired by Myriad Genetics (NASDAQ: MYGN) for $225 million upfront with potential for $185 million in performance-based milestones[2]. The acquisition represented validation of the company's technology and market opportunity, with Assurex Health becoming a wholly-owned subsidiary while maintaining its Mason, Ohio headquarters[4].
Under Myriad's ownership, Assurex Health's GeneSight test continues to expand its clinical footprint in behavioral health and precision psychiatry. As mental health awareness increases and healthcare systems seek evidence-based approaches to reduce medication trial-and-error cycles, pharmacogenomic testing is likely to become increasingly integrated into standard psychiatric care. The company's trajectory reflects how specialized diagnostic technology can create significant value by solving a specific, high-impact clinical problem.
Assurerx Health has raised $78.3M in total across 6 funding rounds.
Assurerx Health's investors include Allos Ventures, Cincy Tech.
Assurerx Health has raised $78.3M across 6 funding rounds. Most recently, it raised $15.0M Series D in December 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2015 | $15.0M Series D | Allos Ventures, Cincy Tech | |
| Dec 1, 2014 | $37.0M Series D | Allos Ventures, Cincy Tech | |
| May 1, 2012 | $13.0M Series C | Allos Ventures, Cincy Tech | |
| Mar 1, 2011 | $11.0M Series B | Allos Ventures, Cincy Tech | |
| Jun 1, 2008 | $2.0M Series A | Cincy Tech | |
| Dec 1, 2007 | $250K Seed | Cincy Tech |